ParagonRx® | Minimize Risk and Optimize Use

Teva Pharmaceutical Industries Ltd. said its chief executive will retire in May and be succeeded by a Bristol-Myers Squibb Co. executive.

In naming Jeremy Levin as its new CEO, Teva, the world's largest generic drug maker, attributed the leadership change to Shlomo Yanai's decision to "move on to a new phase in his career." Mr. Yanai, 59 years old and a veteran of the Israeli Defense Forces, has led Teva for five years as it expanded and diversified into non-generic sectors through a series of acquisitions and partnerships.

"My decision to retire from Teva is based on the desire to ...

[Link to Article]